ADC Therapeutics (ADCT), a commercial-stage oncology-focused biotechnology company, will host a conference call on December 11, 2024, to review preliminary data from its LOTIS-7 Phase 1b open-label clinical trial.
This trial is evaluating the safety and efficacy of the company's lead drug, Zynlonta, in combination with an approved bispecific antibody, i.e. Roche's Glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.